A Phase 2 Open-label Randomised Study of V940 in Combination With BCG versus BCG Monotherapy in Participants with High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

A Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy versus BCG alone in High-Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients

A phase III, randomised, open label, multicentre, global study of durvalumab and bacillus calmette-guerin (BCG) administered as combination therapy veruss BCG alone in high risk, BCG naive non-muscle-invasive bladder cancer patients [POTOMAC]

A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator-controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcinoma Post-radical Resection

A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guerin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy.

A Phase 2 Study Evaluating Adjuvant V940/mRNA-4157+Pembro vs Placebo + Pembro in High-Risk Muscle Invasive Urothelial Carcinoma